Literature DB >> 11986139

Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia.

Christopher M Wilk1, James M Gold, John J Bartko, Faith Dickerson, Wayne S Fenton, Michael Knable, Christopher Randolph, Robert W Buchanan.   

Abstract

OBJECTIVE: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) was designed as a cognitive screening test, providing both a total scale score and five specific cognitive ability index scores. This study examined the test-retest stability of the RBANS in individual patients with schizophrenia relative to a healthy comparison group.
METHOD: A total of 181 patients with schizophrenia or schizoaffective disorder were recruited from three clinical settings. Healthy comparison subjects were recruited as part of the RBANS standardization. Participants were administered one form of the RBANS on one occasion and another form at a later date, with intervals ranging from 1 to 134 days.
RESULTS: Intraclass correlation coefficients for the RBANS total scale were 0.84 for the patients with schizophrenia and 0.77 for the healthy comparison subjects. Confidence intervals and percentile data for the total scale change scores were similar for both groups.
CONCLUSIONS: The RBANS demonstrated reasonable intraclass correlation coefficient test-retest reliability for both schizophrenia patients and healthy comparison subjects. Confidence intervals are comparable to those previously published for the WAIS-R and Wechsler Memory Scale-Revised, suggesting that retest measurement error is not dramatically increased in the RBANS, despite the brevity of the test. These data may serve as an informative guide for using the RBANS to evaluate neuropsychological change on the level of the individual subject.

Entities:  

Mesh:

Year:  2002        PMID: 11986139     DOI: 10.1176/appi.ajp.159.5.838

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  27 in total

1.  Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Authors:  Douglas L Boggs; Deanna L Kelly; Robert P McMahon; James M Gold; David A Gorelick; Jared Linthicum; Robert R Conley; Fang Liu; James Waltz; Marilyn A Huestis; Robert W Buchanan
Journal:  Schizophr Res       Date:  2011-12-03       Impact factor: 4.939

2.  Amyloid Positivity Using [18F]Flutemetamol-PET and Cognitive Deficits in Nondemented Community-Dwelling Older Adults.

Authors:  Dustin B Hammers; Taylor J Atkinson; Bonnie C A Dalley; Kayla R Suhrie; Kevin P Horn; Kelli M Rasmussen; Britney E Beardmore; Lance D Burrell; Kevin Duff; John M Hoffman
Journal:  Am J Alzheimers Dis Other Demen       Date:  2017-04-12       Impact factor: 2.035

3.  Less unique variance than meets the eye: overlap among traditional neuropsychological dimensions in schizophrenia.

Authors:  Dwight Dickinson; James M Gold
Journal:  Schizophr Bull       Date:  2007-08-16       Impact factor: 9.306

4.  The effect of age on postural and cognitive task performance while using vibrotactile feedback.

Authors:  Chia-Cheng Lin; Susan L Whitney; Patrick J Loughlin; Joseph M Furman; Mark S Redfern; Kathleen H Sienko; Patrick J Sparto
Journal:  J Neurophysiol       Date:  2015-01-14       Impact factor: 2.714

Review 5.  Heritability of Neuropsychological Measures in Schizophrenia and Nonpsychiatric Populations: A Systematic Review and Meta-analysis.

Authors:  Gabriëlla A M Blokland; Raquelle I Mesholam-Gately; Timothea Toulopoulou; Elisabetta C Del Re; Max Lam; Lynn E DeLisi; Gary Donohoe; James T R Walters; Larry J Seidman; Tracey L Petryshen
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

6.  A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia.

Authors:  Mario Fioravanti; Olimpia Carlone; Barbara Vitale; Maria Elena Cinti; Linda Clare
Journal:  Neuropsychol Rev       Date:  2005-06       Impact factor: 7.444

7.  Assessing success after cerebral revascularization for ischemia.

Authors:  John E Wanebo; Sepideh Amin-Hanjani; Cynthia Boyd; Terry Peery
Journal:  Skull Base       Date:  2005-08

8.  Relationship of Interferon-γ to Cognitive Function in Midlife Women with Schizophrenia.

Authors:  Kathleen E Wilson; Haley Demyanovich; Leah H Rubin; Heidi J Wehring; Catherine Kilday; Deanna L Kelly
Journal:  Psychiatr Q       Date:  2018-12

9.  The reliability and validity of the MATRICS functional assessment battery.

Authors:  Dawn I Velligan; Megan Fredrick; Jim Mintz; Xueying Li; Maureen Rubin; Sanjay Dube; Smita N Deshpande; Jitendra K Trivedi; Shiv Gautam; Ajit Avasthi; Robert S Kern; Stephen R Marder
Journal:  Schizophr Bull       Date:  2013-11-09       Impact factor: 9.306

10.  Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia.

Authors:  David A Lewis; Raymond Y Cho; Cameron S Carter; Kevin Eklund; Sarah Forster; Mary Ann Kelly; Debra Montrose
Journal:  Am J Psychiatry       Date:  2008-10-15       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.